SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Google Secures Pentagon AI Deal for Classified Projects 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
NEW YORK, April 13, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Argos Therapeutics, Inc. (NASDAQ:ARGS) who purchased shares between February 7, 2014 and February 21, 2017. The action, which was filed in the United States District Court for the Middle District of North Carolina, alleges that the Company violated federal securities laws.
The complaint alleges that Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017, despite positive statements made by the Company, Argos announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.
Shareholders have until May 15, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/argos-therapeutics-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
